EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular and pharmacodynamic insights into β-lactam therapy for high-inoculum Enterobacter cloacae complex infections

Ashlan J Kunz Coyne iD, Rachel Gray, Elizabeth May, Hunter Curry, Nicole Slain, Chris Delcher, Eugene Shin

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01170-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Ashlan J Kunz Coyne und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Kentucky College of Pharmacy, Lexington, Kentucky, USA. Hauptthemen laut MEDLINE: Enterobacter cloacae, Anti-Bacterial Agents, beta-Lactams, Enterobacteriaceae Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Society of Infectious Diseases Pharmacists.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High-inoculum Enterobacter cloacae complex (ECC) infections challenge β-lactam therapy due to β-lactamase-mediated resistance and the inoculum effect, where high bacterial densities amplify resistance and worsen outcomes. We evaluated the pharmacodynamic efficacy of cefepime, meropenem, ertapenem, meropenem–vaborbactam, and ceftazidime–avibactam against three high-inoculum (10⁹ colony-forming unit [CFU]/g) ECC isolates (0008, 0032, and 0060) harboring diverse β-lactamases using a 96 h simulated endocardial vegetation (SEV) model with humanized exposures. Bactericidal activity, resistance emergence, and β-lactamase expression were assessed. Cefepime failed in all isolates, with SEV growth from +0.4 to +1.6 log 10 CFU/g and minimum inhibitory concentrations (MICs) increasing from 2–8 µg/mL to >64 µg/mL in 0008, 0032, and 0060, coinciding with AmpC β-lactamase (ACT) induction up to 16.1-fold (0032). In 0060, cefepime failed, whereas meropenem displayed infusion-dependent efficacy: the 3 h infusion achieved bactericidal killing (−4.6 log 10 CFU/g), while the 30 min infusion produced partial killing (–2.9 log 10 CFU/g). Meropenem failed in 0032 (+1.1 log 10 CFU/g), with ACT-16 induction reaching 14.6-fold. Ertapenem produced initial bactericidal activity in 0060 (–3.2 log 10 CFU/g) but regrowth to –1.9 log 10 CFU/g by 96 h, accompanied by ACT-89 expression rising 26-fold. Meropenem–vaborbactam was bactericidal in 0008 (–4.6 log 10 CFU/g) and 0032 (–3.6 log 10 CFU/g) with stable MICs and minimal β-lactamase induction. Ceftazidime–avibactam achieved bactericidal activity in 0008 (–4.9 log 10 CFU/g) but only bacteriostatic activity in 0032 (–1.2 log 10 CFU/g), with modest KPC-3 and ACT-16 upregulation (~1.7- to 2.3-fold). β-Lactamase diversity and inoculum effects limit β-lactam efficacy in high-inoculum ECC infections. Meropenem–vaborbactam showed consistent activity, and prolonged meropenem infusion benefited select isolates. Variable ceftazidime–avibactam efficacy reinforces aligning β-lactam selection with underlying β-lactamase mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enterobacter cloacaeAnti-Bacterial Agentsbeta-LactamsEnterobacteriaceae InfectionsMicrobial Sensitivity Testsbeta-LactamasesMeropenemCefepimeHumansAzabicyclo CompoundsErtapenemCeftazidimeCephalosporinsDrug CombinationsThienamycinsBoronic Acidsbeta-Lactam ResistanceHeterocyclic Compounds, 1-Ring

Stichwörter der Autor:innen

AmpC-producing EnterobacteralesEnterobacter cloacae complexinoculum effectsimulated endocardial vegetation modelβ-lactam/β-lactamase inhibitorsβ-lactamase expression

Substanzen

Anti-Bacterial Agentsbeta-LactamasesMeropenembeta-LactamsCefepimeAzabicyclo CompoundsErtapenemCeftazidimeCephalosporinsDrug Combinations

Autor:innen und Institutionen

  • University of Kentucky College of Pharmacy, Lexington, Kentucky, USA.
  • University of Kentucky HealthCare, Lexington, Kentucky, USA.
  • Institute for Pharmaceutical Outcomes and Policy, University of Kentucky College of Pharmacy, Lexington, Kentucky, USA.

ORCID-Profile: Ashlan J Kunz Coyne

Förderung

  • Society of Infectious Diseases Pharmacists

Zitieren

APA

Kunz Coyne, A. J., Gray, R., May, E., Curry, H., Slain, N., Delcher, C., & Shin, E. (2025). Molecular and pharmacodynamic insights into β-lactam therapy for high-inoculum Enterobacter cloacae complex infections. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01170-25

Vancouver

Kunz Coyne AJ, Gray R, May E, Curry H, Slain N, Delcher C, et al. Molecular and pharmacodynamic insights into β-lactam therapy for high-inoculum Enterobacter cloacae complex infections. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01170-25

BibTeX
@article{KunzCoyne2025,
  author = {Kunz Coyne, Ashlan J and Gray, Rachel and May, Elizabeth and Curry, Hunter and Slain, Nicole and Delcher, Chris and Shin, Eugene},
  title = {Molecular and pharmacodynamic insights into β-lactam therapy for high-inoculum Enterobacter cloacae complex infections},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01170-25}
}
Kostenlos starten →